More Pharmac funding and earlier screening
Add $604m to Pharmac over four financial years and deliver earlier screening, with some screening commitments already funded.
Our assessment & details
Our assessment
AnalysisStrengths
- Sets screening deadlines and multi-year Pharmac funding, while the papers distinguish new spending from screening services already funded.Evidence 1Evidence 2Evidence 3
Trade-offs & risks
- Partly financed by a $431.2m aid reduction over four years, leaving less funding for overseas assistance outside the Pacific.Evidence 1Evidence 2Evidence 3
Open questions
- What capacity supports earlier screening, and how does the narrative's further $45.6m MFAT saving relate to the tables?Evidence 1Evidence 2
Party proposal
National proposes an additional $604 million for Pharmac over four financial years, more clinical trials and earlier cancer screening. It would lower bowel screening to age 50 and extend breast screening to age 74 by 2029, with free cervical screening from March 2027.
- Who it covers
- Patients eligible for funded medicines and screening programmes. The cervical-screening proposal covers women aged 25–69; Pharmac would decide which medicines receive funding.
- Timing
- Pharmac uplift in 2027/28–2030/31. Cervical screening from March 2027; bowel and breast screening targets by 2029.
- Cost & funding stated by the party
- The policy table shows $351.1m net operating cost and $41.5m capital over 2027/28–2030/31: Pharmac $604m plus bowel screening $178.3m less aid savings $431.2m. All appear in the new plan as separate rows. The narrative’s further $45.6m MFAT saving remains unidentified in the tables, which count fewer savings. Other screening commitments are already funded or use baselines.
Sources reviewed
National: medicines and earlier care Policy page · Publication date not stated
National: medicines and screening policy (PDF) Policy paper · Publication date not stated
National: consolidated fiscal plan Policy paper · Published